TNPH Tian An Pharmaceutical Co Ltd (PK)

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SEC File Number 0-26947
CUSIP Number 09060V 10 94

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):

[ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR

Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein. _________________________________

Full Name of Registrant: Tian'an Pharmaceutical Co., Ltd.

Former Name if Applicable: N/A

Address of Principal Executive Office (Street and Number)

Level 11, International Trade Centre No.196 Xiaozhai East Road

City, State and Zip Code

Xi'an, China

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, or transition report or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form l0-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, or N-SAR, or the transition report or portion thereof could not be filed within the prescribed time period.

The Company did not complete its financial statements in sufficient time so as to allow the filing of the 10-Q report by May 15, 2008. As a result, additional time is needed to file the report.

(1) Name and telephone number of person to contact in regard to this notification

William T. Hart (303) 839-0061
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports
 required under Section 13 or 15(d)
 of the Securities Exchange Act of
 1934 during the preceding l2 months
 (or for such shorter period that
 the registrant was required to file
 such reports) been filed? If answer
 is no, identify report(s). [X] Yes [ ] No

 (3) Is it anticipated that any significant
 change in results of operations from
 the corresponding period for the last
 fiscal year will be reflected by the
 earnings statements to be included
 in the subject report or portion thereof? [ ] Yes [X] No

 If so: attach an explanation of the
 anticipated change, both narratively and
 quantitatively, and, if appropriate, state
 the reasons why a reasonable estimate of
 the results cannot be made.

Tian'an Pharmaceutical Co., Ltd.
(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

May 15, 2008 By: /s/ William T. Hart
 William T. Hart
 Hart & Trinen, LLP
 1624 Washington St.
 Denver, CO 80203

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

Tian An Pharmaceutical (PK) (USOTC:TNPH)
Historical Stock Chart
From May 2024 to May 2024

Tian An Pharmaceutical (PK) (USOTC:TNPH)
Historical Stock Chart
From May 2023 to May 2024